Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shandong Weigao Orthopaedic Device Co (688161) Fair Value & Analysis

Healthcare · CN · Market cap 8.9B CNY

Price¥21.90
Fair Value¥14.78
Upside-32.5%
Quality95/100
Evidence: High Range ¥11.08 – ¥18.47

Analysis

Shandong Weigao Orthopaedic Device Co (688161) currently trades at ¥21.90, while our model-based Fair Value estimate is ¥14.78 — implying the stock looks roughly 32.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Shandong Weigao Orthopaedic Device Co., Ltd. engages in research, development, production, and sales of orthopedic medical devices. The company offers orthopedic implantable medical devices and orthopedic surgical instruments. It also provides spinal products, such as internal fixation systems for the cervical and thoracic/lumbar spine, and interbody fusion devices; trauma-related products include locking plate systems, intramedullary nail systems, hollow screw systems, and external fixation systems; and joint products, including hip joint prosthesis systems, knee joint prosthesis systems, and shoulder joint prosthesis systems. In addition, the company sports medicine products comprise cruciate ligament reconstruction system, meniscus repair system, and sports trauma system; craniofacial surgery products; and orthopedic diagnostic equipment. The company was founded in 2005 and is based in Weihai, China. Shandong Weigao Orthopaedic Device Co., Ltd. operates as a subsidiary of Shandon…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +19%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.